See more : nms Holdings Corporation (2162.T) Income Statement Analysis – Financial Results
Complete financial analysis of Guardion Health Sciences, Inc. (GHSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardion Health Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Great Panther Mining Limited (0R0D.L) Income Statement Analysis – Financial Results
- Signify N.V. (PHPPY) Income Statement Analysis – Financial Results
- UC&GN International Corp. (3603.TWO) Income Statement Analysis – Financial Results
- Air Canada (AC.TO) Income Statement Analysis – Financial Results
- TMS Co., Ltd. (4891.T) Income Statement Analysis – Financial Results
Guardion Health Sciences, Inc. (GHSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.guardionhealth.com
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.25M | 11.05M | 7.23M | 1.89M | 902.94K | 942.15K | 437.35K | 141.03K | 112.81K | 164.58K | 260.36K |
| Cost of Revenue | 6.85M | 6.53M | 4.12M | 1.95M | 341.32K | 398.18K | 175.47K | 75.70K | 50.07K | 145.53K | 168.88K |
| Gross Profit | 5.39M | 4.52M | 3.11M | -56.79K | 561.62K | 543.97K | 261.88K | 65.33K | 62.74K | 19.05K | 91.48K |
| Gross Profit Ratio | 44.04% | 40.91% | 43.00% | -3.01% | 62.20% | 57.74% | 59.88% | 46.32% | 55.61% | 11.58% | 35.14% |
| Research & Development | 150.68K | 193.80K | 64.36K | 160.98K | 194.31K | 231.85K | 259.46K | 64.03K | 401.91K | 43.44K | 259.79K |
| General & Administrative | 7.48M | 9.58M | 11.20M | 6.83M | 7.43M | 4.93M | 4.68M | 3.31M | 5.61M | 638.00K | 616.70K |
| Selling & Marketing | 1.70M | 2.07M | 2.32M | 1.45M | 1.87M | 1.52M | 599.93K | 389.11K | 180.13K | 46.77K | 51.60K |
| SG&A | 9.19M | 11.65M | 13.53M | 8.28M | 9.30M | 6.46M | 5.28M | 3.70M | 5.79M | 684.77K | 668.30K |
| Other Expenses | 394.55K | 3.57M | 10.14M | 0.00 | 1.22M | 0.00 | 0.00 | 174.04K | -1.70M | 0.00 | 0.00 |
| Operating Expenses | 9.73M | 11.84M | 13.59M | 8.45M | 9.50M | 6.69M | 5.54M | 3.76M | 6.19M | 728.21K | 928.09K |
| Cost & Expenses | 16.58M | 18.37M | 17.72M | 10.39M | 9.84M | 7.09M | 5.72M | 3.84M | 6.24M | 873.74K | 1.10M |
| Interest Income | 379.52K | 152.57K | 1.80K | 7.27K | 258.37K | 0.00 | 0.00 | 0.00 | 0.00 | 611.34K | 406.07K |
| Interest Expense | 0.00 | 15.35M | 0.00 | 7.27K | 258.37K | 2.29K | 23.73K | 1.10M | 752.95K | 0.00 | 0.00 |
| Depreciation & Amortization | 19.42K | 1.25M | 910.37K | 219.60K | 625.79K | 295.67K | 118.82K | 60.13K | 53.74K | 43.23K | 8.84K |
| EBITDA | -3.92M | -6.07M | -9.70M | -8.34M | -9.99M | -7.47M | -5.16M | -4.58M | -8.03M | -665.92K | -827.77K |
| EBITDA Ratio | -32.02% | 15.22% | -132.36% | -438.27% | -966.13% | -620.71% | -1,180.44% | -2,578.07% | -6,892.95% | -404.61% | -317.94% |
| Operating Income | -4.34M | 432.68K | -10.48M | -8.55M | -8.93M | -6.14M | -5.28M | -3.95M | -6.39M | -709.15K | -836.61K |
| Operating Income Ratio | -35.40% | 3.92% | -144.94% | -452.51% | -989.37% | -652.09% | -1,207.60% | -2,797.79% | -5,663.22% | -430.88% | -321.33% |
| Total Other Income/Expenses | 4.49M | 2.50M | 1.80K | -19.93K | -381.37K | -1.62M | -23.73K | -1.80M | -2.45M | -611.34K | -406.07K |
| Income Before Tax | 158.03K | -14.92M | -24.75M | -8.57M | -10.88M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
| Income Before Tax Ratio | 1.29% | -135.05% | -342.11% | -453.56% | -1,204.77% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
| Income Tax Expense | 0.00 | 15.35M | 672.79K | 7.27K | 258.37K | -1.62M | 0.00 | 1.10M | -946.66K | 0.00 | 0.00 |
| Net Income | 158.03K | -30.28M | -24.75M | -8.58M | -11.14M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
| Net Income Ratio | 1.29% | -274.01% | -342.11% | -453.95% | -1,233.38% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
| EPS | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.39 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
| EPS Diluted | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.09 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
| Weighted Avg Shares Out | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.70K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
| Weighted Avg Shares Out (Dil) | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.91K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
Doane University in Nebraska Launches Cannabis Course | Grizzle
The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan -
Reflections on suicide of Professor Bongani Mayosi, persecuted to death - Ed Herbst - BizNews.com
Source: https://incomestatements.info
Category: Stock Reports